Document Detail

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective.
MedLine Citation:
PMID:  24973113     Owner:  NLM     Status:  Publisher    
BACKGROUND: Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study demonstrated that the rates of stroke and systemic embolism with dabigatran (an oral direct thrombin inhibitor) were similar to or lower than those with warfarin.
AIMS: To estimate the cost-effectiveness, from a French payer perspective, of dabigatran (150 or 110mg bid for patients<or≥80 years, respectively) versus warfarin.
METHODS: Cost-effectiveness was modeled using a Markov model in a cohort of 10,000 patients with atrial fibrillation followed over their lifetime. Events accounted for included ischemic stroke, systemic embolism, transient ischemic attack, hemorrhage, myocardial infarction and death. The model patient population matched the RE-LY patients. Dabigatran was compared with "trial-like" warfarin and "real-world" prescribing. Risks of clinical events were obtained from RE-LY. Event and follow-up costs were based on the French national tariff or published literature. Clinical events, QALYs, total costs and incremental cost-effectiveness ratios (ICERs) were calculated.
RESULTS: The ICERs of dabigatran compared with "trial-like" warfarin and "real-world" prescribing were €15,838/QALY and €7473/QALY, respectively. Deterministic and probabilistic sensitivity analyses showed these to be robust to uncertainty and variability in the model parameters. The ICER for dabigatran was below €24,000/QALY or €36,000/QALY in 71% or 92%, respectively, of the simulations when compared with "trial-like" warfarin and 100% and 100%, respectively, when compared with "real-world" prescribing.
CONCLUSION: This study suggests that the use of dabigatran in French atrial fibrillation patients is cost-effective, according to usually accepted thresholds.
Julie Chevalier; Olivier Delaitre; Florence Hammès; Gérard de Pouvourville
Related Documents :
9524793 - The effects of gentamicin on the activities of glutathione peroxidase and superoxide di...
23570203 - Advantages of direct thrombin inhibition in high- and low-risk patients.
18721523 - Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hyp...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-24
Journal Detail:
Title:  Archives of cardiovascular diseases     Volume:  -     ISSN:  1875-2128     ISO Abbreviation:  Arch Cardiovasc Dis     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101465655     Medline TA:  Arch Cardiovasc Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanical circulatory support for infants and small children.
Next Document:  Novel method of surgical preparation for transcatheter completion of Fontan circulation: Creation of...